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Abstract
Background: The present developments in colon surgery are characterized by two innovations: the introduction of 
the laparoscopic operation technique and fast recovery programs such as the Enhanced Recovery After Surgery (ERAS) 
recovery program. The Tapas-study was conceived to determine which of the three treatment programs: open 
conventional surgery, open 'ERAS' surgery or laparoscopic 'ERAS' surgery for patients with colon carcinomas is most 
cost minimizing?
Method/design: The Tapas-study is a three-arm multicenter prospective cohort study.
All patients with colon carcinoma, eligible for surgical treatment within the study period in four general teaching
hospitals and one university hospital will be included. This design produces three cohorts: Conventional open surgery
is the control exposure (cohort 1). Open surgery with ERAS recovery (cohort 2) and laparoscopic surgery with ERAS
recovery (cohort 3) are the alternative exposures. Three separate time periods are used in order to prevent attrition bias.
Primary outcome parameters are the two main cost factors: direct medical costs (real cost price calculation) and the
indirect non medical costs (friction method). Secondary outcome parameters are mortality, complications, surgical-
oncological resection margins, hospital stay, readmission rates, time back to work/recovery, health status and quality of
life.
Based on an estimated difference in direct medical costs (highest cost factor) of 38% between open and laparoscopic
surgery (alfa = 0.01, beta = 0.05), a group size of 3×40 = 120 patients is calculated.
Discussion: The Tapas-study is three-arm multicenter cohort study that will provide a cost evaluation of three 
treatment programs for patients with colon carcinoma, which may serve as a guideline for choice of treatment and 
investment strategies in hospitals.
Trial registration: ISRCTN44649165.
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Usual care
The standard of care for colon carcinoma patients is
changing. Traditionally operative treatment means an
open resection (i.e. laparotomy) and 'conventional'
patient-tailored recovery. In the last decade laparoscopic
(assisted) colon surgery is introduced as a valuable alter-
native [1-5]. Over the last five years Enhanced Recovery
After Surgery (ERAS) programs have been introduced
and in many hospitals these alternatives gradually replace
conventional care [6-11].
Equality of long term clinical (and oncological) effec-
tiveness of laparoscopic surgery as well as ERAS recovery
has been proven in literature [4,5,12-18]. To date how-
ever, strong evidence of cost minimization effects of these
innovations is lacking.
Many hospitals are at a stage of investing large amounts
in endoscopic operation theatres ('endosuites'). If laparo-
scopic surgery does not result in added cost effectiveness
compared to open ERAS programs (or traditional open
programs), future investments in endoscopic endosuites
may be ill-advised. With this in mind a prospective
cohort study is set up comparing traditional open, open-
ERAS and laparoscopic-ERAS colon surgery.
Health care problem
Costs of conventional open colon surgery is substantial.
With approximately 9000 operations for colon carcinoma
in the Netherlands annually, direct medical costs are esti-
mated at 38.6 million euro [19].
Overall cost effectiveness studies on laparoscopic and
open colon surgery have shown little differences [14,20].
This allows us to focus merely on direct medical costs
accompanying laparoscopic surgery, showing an increase
to 65.3 million euro for laparoscopic surgery (difference
of 26.7 million euro per year). On top of these costs, hos-
pital investments in laparoscopic operation theatres
should be taken into account. Many Dutch hospitals are
currently planning such investments. Reduction of time
back to work (indirect non-medical costs) due to
enhanced recovery from laparoscopy could compensate
for these extra costs. However this cost minimization
issue has never been clearly investigated.
Investment costs of ERAS recovery programs (mainly
ward personnel costs and training facilities) have not
been well established so far. Especially direct medical
costs due to intensified activities of ward personnel
should be considered. From a cost minimization point of
view, reduction of hospital stay and enhanced rehabilita-
tion to normal activity/work should equalize the
increased personnel costs. This issue of presumed cost
savings has not been raised so far nor evaluated.
In line with the two aforementioned cost minimization
questions, a third question arises: which investment (in
ERAS recovery programs, in laparoscopic operation the-
atres and -surgery or a combination of both) is most valu-
able for hospitals in near future.
Methods/design
Study objectives
The current study has the following two objectives:
To discern the most cost minimizing surgical peri-
operative treatment program for colon cancer patients
and to indicate justification or rejection of investments in
these hospitals.
To supplement the lack of knowledge in literature on
cost minimizing differences between the three treatment
programs and to provide recommendations on further
development in the operative treatment of colon carcino-
mas from an economic point of view.
Study design
The Tapas-study is a multicenter prospective cohort
study. Randomised Controlled Trials are considered to
give the highest level of evidence. Since randomization
produces the best comparable groups, which is method-
ological the best manner to compare the intervention
group with the conventional/standard group. However,
cohort studies can easily separate complex multidisci-
plinary treatment programs such as ERAS into time and
place, preventing an important bias: the attrition bias. An
attrition bias occurs when elements of the control and
alternative intervention mix and hence influences out-
come. This explains why studies with ERAS are often cor-
rectly designed as cohort studies and not as randomized
controlled trials [21,22].
Conventional open surgery is the control exposure
(cohort 1). Open surgery with ERAS recovery (cohort 2)
and laparoscopic surgery with ERAS recovery (cohort 3)
are the alternative exposures. Three separate consecutive
time periods are used in order to prevent attrition bias.
Before each new cohort starts a quality control assess-
ment will be carried out by the expert project advisors
from the research group on ERAS recovery and laparo-
scopic surgery.
Primary and secondary endpoints
The primary endpoint of the Tapas-study are costs, both
direct medical en indirect non medical costs. Direct med-
ical costs are defined as the total costs of medical
resources used for diagnostics, therapy, revalidation and
peri-operative care. Indirect non medical costs are
defined as the total costs due to loss of productivity mea-
sured by the time back to work.
Secondary endpoints are total postoperative hospital
stay in days, including hospital stay ofpatients who are
readmitted within 30 days after surgery and quality of life
and health status after 6 weeks, 3 months and one year
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sured by two validated questionnaires; Short Form 36
(SF-36) and the WHOQOL-100. Further secondary end-
points are complications and mortality within 30 days
after surgery, readmission rates, time back to work and
differences in surgical-oncological radicality between
open and laparoscopic surgery.
Participating centers
Five Dutch hospitals including one university medical
centre en four general teaching hospitals, comparable by
size and expertise, will enroll patients.
Study population
The study population consists of all patients with colon
carcinoma, eligible for surgical treatment within the
study period January 2007 to July 2010.
Inclusion criteria are: patients with a primary colon
carcinoma, over 18 years of age, ASA I en II, who give
informed consent.
Exclusion criteria are: pregnancy, ASA III-IV, previous
abdominal surgery and metastasized illness.
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. All collected data will be kept confidential at
all times. The independent medical ethics committees of
all participating hospitals have approved the study proto-
col. Prior to inclusion, written informed consent will be
obtained from all patients.
The proposed cohort study carries no additional risks,
as extra diagnostics or other than established treatment
methods will not be used.
Study outline
Inclusion and informed consent is obtained at the outpa-
tient clinic. The patient is presented the appropriate
treatment modality according to the current cohort, after
which informed consent for that specific treatment is
obtained.
Patients assigned to cohort 2 and 3 with ERAS recovery
will receive additional information about the ERAS pro-
gram by an ERAS nurse and an anesthesiologist prior to
hospital admittance. All patients in cohort 2 and 3 will be
admitted to a ward, were nurses and medical staff are
trained in the ERAS program, and the ERAS protocol
used is checked by the project experts.
Patients included into the third cohort will be operated
by an experienced laparoscopic surgeon. The require-
ment for surgeons to perform laparoscopic colon surgery
is 20 completed procedures.
To accomplish standardization and quality of care of
the participating hospitals, prior to the start of the study
every clinic is visited and agreements will be made on
peri-operative care and the surgical procedures. For
cohort 1 a protocol which defines traditional/conven-
tional care will be uses by every hospital. Before cohort 2,
an ERAS-expert panel visits the hospitals to check and
agree upon the ERAS elements used in the clinic. A mini-
mum number of 8 ERAS elements or more will be consid-
ered as ERAS peri-operative care. Before cohort 3, a
quality control assessment will be performed in every
hospital by experts on laparoscopic colon surgery, also
accomplishing standardization of the laparoscopic meth-
ods used.
Discharge criteria
Whether the discharge criteria are met will be assessed
and scored on every postoperative day. Discharge criteria
include adequate pain control with oral analgesics, no
nausea and ability to take solid foods, intestinal passage
of flatus and/or stool, mobilization and self support as




The analysis will be performed in accordance with the
intention to treat principle.
Sample size calculation
We used an extensive table to calculate all direct medical
costs including overhead and consultant costs for open
and laparoscopic colon surgery for an average Dutch hos-
pital. The main cost differences were due to the differ-
ence in operating time, use of (disposable) laparoscopic
instruments and hospital stay. Based on our costs calcula-
tion, for each patient the difference in direct medical
costs between laparoscopic colectomy en open colectomy
is 2967 euro (38%). Considering approximately 9000
colon carcinoma operations performed annually in the
Netherlands http://www.prismant.nl, the hypothetical
direct costs of all 'open' colectomies performed are 38.7
million euro. The hypothetical direct costs of laparoscop-
ically colectomies for the Netherlands are 65.3 million
euro. Performing all colectomies in the Netherlands by a
laparoscopic technique would result in 26.7 (= 38%) euro
extra direct costs compared to performing all colectomies
by the open technique.
Power calculation of the study
p1 (direct medical cost of laparoscopic colon surgery in
the Netherlands) = 100 %
p2 (direct medical cost of open colon surgery in the
Netherlands) = 62%
alfa = 0.01, beta = 0.05, f = 17.8
n 1 1 1 62 1 62
38 38
17 8 29 patients in each





00 00 00 00
 group
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in literature form other countries, the number needed in
each group would be n = 43. Therefore a more conserva-
tive trial size of 3 × 40 = 120 patients is taken into
account.
Economic evaluation
In the cost minimization study direct medical costs and
the indirect non medical costs are estimated. For the
direct medical costs the method of real cost price calcula-
tion will be used. This will include the additional costs of
laparoscopy, of ERAS care, as well as the differences due
to complications and readmission. For indirect non medi-
cal costs the friction cost method will be used [23]. This
also allows us to limit the study period to one year post
operatively. On the direct non medical costs and indirect
medical costs assumptions of equality are made and these
costs are not accounted for in this study.
Data collection and monitoring
Data are collected in a specially designed case-record
form, both in the outpatient clinic as during hospital stay.
Preoperatively, as well as 6 weeks, 12 weeks and one year
postoperatively quality of life questionnaires (SF-36/
GIQLI, Vaizey) are filled in by the patient.
The overall study period is 30 months: three cohort
periods followed by one year of data analysis and synthe-
sis. Because of the end points used (i.e. direct medical
costs and indirect medical costs due to rehabilitation to
normal work/activity), a longer follow up is not indicated.
At one year all important differences in recovery and
rehabilitation to normal life and work can be analyzed.
Middle and long term outcomes measures (like oncologi-
cal recurrences and late secondary complications like
adhesions and incisional hernias) will not be included.
Histopathological result of resections will be evaluated
and compared.
There will be regular contact between the study coordi-
nators and the participating centers, and all included data
will be monitored by a research fellow.
Discussion
Extensive literature exists on ERAS and laparoscopic
colon surgery. Regarding the comparison between ERAS
recovery and conventional care level 1a evidence exists,
showing at least equality and possibly improvement of
clinical outcome [18]. Four level 1a reports exist on open
versus laparoscopic colon surgery[2,3,12,17]: generally
short term results of laparoscopic surgery are better, but
no differences on middle and long term clinical outcome
are found. Concern has existed on long term oncological
outcome, but four level 1b studies (RCT's) have indicated
equality in middle and long term (5 years) oncological
outcome [4,13,15,16]. One level 1b study indicates that
ERAS recovery is as effective in open and laparoscopic
surgery, which theoretically biases and diminishes the
superiority in short term results of laparoscopic com-
pared to open surgery [6].
Abovementioned studies have convincingly shown that
the results of ERAS recovery and/or laparoscopic surgery
are at least comparable to those of the conventional surgi-
cal approach in colon carcinoma. Long term clinical
results as well as surgical-oncological results are equal.
One RCT (level 1b) and three level 2b stud-
ies[14,20,24,25] on cost effectiveness of open versus lap-
aroscopic surgery exist. Ignoring possible bias
abovementioned, higher operation theatre expenses are
leveled down by shorter hospital stays. Only one level 2b
cost effectiveness study is available on open conventional
recovery versus open ERAS recovery or the combined
laparoscopic ERAS programs [26].
No ongoing studies focusing on cost minimization are
reported so far. This study seeks to improve the lack of
cost minimization data in literature, and may therefore
provide important information on the justification of
changing treatment policies and investments in hospital
facilities for colon surgery.
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